U.S. Markets closed

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
Add to watchlist
66.50-0.50 (-0.75%)
At close: 05:29PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close67.00
Bid65.90 x 0
Ask66.20 x 0
Day's Range64.00 - 68.10
52 Week Range63.00 - 140.00
Avg. Volume7,250
Market Cap746.542M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-6.48
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est300.00
  • GlobeNewswire

    Nomination Committee appointed for the 2022 Annual General Meeting (AGM) in Infant Bacterial Therapeutics (IBT).

    Stockholm, October 29, 2021. The Chairman of IBT has established a Nomination Committee for the AGM, which is planned to be held on May 4, 2022. The Nomination Committee is composed, according to descion by the AGM of 2021, of members appointed by the three largest shareholders in terms of voting rights, wich all have accepted the invitation to join the committee. The following members were the largest shareholders in terms of voting rights according to the shareholders register as of June 30, 2

  • GlobeNewswire

    Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021

    Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021 Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the final study in our clinical development program with our drug candidate IBP-9414, which contains Lactobacillus reuteri as the active substance. The active substance is a naturally occurring bacterial strain found in women's breast milk. The goal of our development is to offer physicians a unique treatme

  • GlobeNewswire

    Next recruitment milestone reached in IBT’s Phase III Study.

    Infant Bacterial Therapeutics (IBT) announces that the company has reached the next important milestone after recruiting 600 premature infants in the ongoing Clinical Phase III study of IBP-9414. According to the study protocol, a safety and futility analysis will now be performed during which the recruitment will continue. On September 22nd the company announced the reopening of stratum A (weights 500 to 749 grams) after the independent Data Monitoring Committee (DMC) completed an additional sa